Mesoblast presented positive results from the phase 3 DREAM-HF trial evaluating rexlemestrocel-L in patients with New York Heart Association (NYHA) class II and class III…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.